Icon Wealth Advisors LLC Acquires 3,141 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Icon Wealth Advisors LLC lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 57.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,646 shares of the medical research company’s stock after buying an additional 3,141 shares during the period. Icon Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $5,025,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. IFG Advisory LLC bought a new position in Thermo Fisher Scientific in the 4th quarter valued at about $220,000. McGlone Suttner Wealth Management Inc. acquired a new position in Thermo Fisher Scientific during the fourth quarter valued at approximately $96,000. Blue Trust Inc. boosted its holdings in shares of Thermo Fisher Scientific by 6.0% in the 4th quarter. Blue Trust Inc. now owns 851 shares of the medical research company’s stock valued at $430,000 after purchasing an additional 48 shares in the last quarter. ICICI Prudential Asset Management Co Ltd bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $4,538,000. Finally, Wells Trecaso Financial Group LLC grew its position in Thermo Fisher Scientific by 0.4% in the fourth quarter. Wells Trecaso Financial Group LLC now owns 10,468 shares of the medical research company’s stock valued at $5,556,000 after acquiring an additional 37 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

TMO has been the topic of a number of research analyst reports. TD Cowen raised their price target on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Evercore ISI decreased their target price on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Royal Bank of Canada increased their price target on Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. The Goldman Sachs Group upped their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $650.00 price target (up from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $618.94.

Thermo Fisher Scientific Trading Up 1.8 %

Shares of NYSE:TMO traded up $10.94 during mid-day trading on Tuesday, hitting $615.06. The company had a trading volume of 1,614,294 shares, compared to its average volume of 1,565,375. The company has a market capitalization of $234.78 billion, a PE ratio of 39.45, a price-to-earnings-growth ratio of 2.83 and a beta of 0.77. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $615.74. The firm has a fifty day moving average price of $563.71 and a 200 day moving average price of $566.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, beating the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The firm had revenue of $10.54 billion for the quarter, compared to analyst estimates of $10.50 billion. During the same quarter in the prior year, the business earned $5.15 earnings per share. The business’s quarterly revenue was down 1.4% compared to the same quarter last year. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.25%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s payout ratio is 10.01%.

Insider Activity at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $1,201,700.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at $7,860,920.55. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,238,340.48. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $1,201,700.00. Following the transaction, the senior vice president now directly owns 13,083 shares in the company, valued at $7,860,920.55. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,784 shares of company stock valued at $9,801,825. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.